Corpus ID: 38604161

Small Intestinal Bacterial Overgrowth: Novel Insight in the Pathogenesis and Treatment of Irritable Bowel Syndrome

@article{Bourboulis2009SmallIB,
  title={Small Intestinal Bacterial Overgrowth: Novel Insight in the Pathogenesis and Treatment of Irritable Bowel Syndrome},
  author={E. J. G. Bourboulis and M. Tzivras},
  journal={Annals of Gastroenterology},
  year={2009},
  volume={22},
  pages={77-81}
}
  • E. J. G. Bourboulis, M. Tzivras
  • Published 2009
  • Medicine
  • Annals of Gastroenterology
  • A total of 65-84% of patients with irritable bowel syndrome (IBS) presents with small intestinal bacterial overgrowth (SIBO). SIBO is defined as the presence of more than 105 cfu/ml of colonic type bacteria in the lumen of the small bowel. It is more common in patients with IBS and predominant bloating and diarrhea. Based on the implication of SIBO in the pathogenesis of IBS, six trials have been conducted and analyzed in this review aiming to define a role of rifaximin for the management of… CONTINUE READING
    2 Citations

    References

    SHOWING 1-10 OF 31 REFERENCES
    Rifaximin Treatment for Symptoms of Irritable Bowel Syndrome
    • 33
    The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome
    • 410
    • PDF
    Review of rifaximin as treatment for SIBO and IBS.
    • M. Pimentel
    • Medicine
    • Expert opinion on investigational drugs
    • 2009
    • 66
    Diagnosis of small intestinal bacterial overgrowth: the challenges persist!
    • 32
    Nuances in treating irritable bowel syndrome.
    • C. Frissora
    • Medicine
    • Reviews in gastroenterological disorders
    • 2007
    • 5
    Small Intestinal Bacterial Overgrowth Recurrence After Antibiotic Therapy
    • 86